Relationship of fatigue with cognitive performance in women with early-stage breast cancer over 2 years
- PMID: 30761683
- PMCID: PMC6538270
- DOI: 10.1002/pon.5028
Relationship of fatigue with cognitive performance in women with early-stage breast cancer over 2 years
Abstract
Objective: Fatigue and cognitive dysfunction are major concerns for women with early-stage breast cancer during treatment and into survivorship. However, interrelationships of these phenomena and their temporal patterns over time are not well documented, thus limiting the strategies for symptom management interventions. In this study, changes in fatigue across treatment phases and the relationship among fatigue severity and its functional impact with objective cognitive performance were examined.
Methods: Participants (N = 75) were assessed at five time points beginning prior to chemotherapy to 24 months after initial chemotherapy. Fatigue severity and impact were measured on the Brief Fatigue Inventory. Central nervous system (CNS) Vital Signs was used to measure performance based cognitive testing. Temporal changes in fatigue were examined, as well as the relationship between fatigue and cognitive performance, at each time point using linear mixed effect models.
Results: Severity of fatigue varied as a function of phase of treatment. Fatigue severity and its functional impact were moderate at baseline, increased significantly during chemotherapy, and returned to near baseline levels by 2 years. At each time point, fatigue severity and impact were significantly associated with diminished processing speed and complex attention performance.
Conclusions: A strong association between fatigue and objective cognitive performance suggests that they are likely functionally related. That cognitive deficits were evident at baseline, whereas fatigue was more chemotherapy dependent, implicates that two symptoms share some common bases but may differ in underlying mechanisms and severity over time. This knowledge provides a basis for introducing strategies for tailored symptom management that vary over time.
Keywords: breast cancer; cancer; chemobrain; chemotherapy; cognition; fatigue; longitudinal; oncology.
© 2019 John Wiley & Sons, Ltd.
Conflict of interest statement
Conflict of Interest Statement: Authors Gullett, Cohen, Yang, Menzies, Fieo, Kelly, Starkweather, Jackson-Cook, and Lyon declare that they have no conflict of interest.
Figures
References
-
- Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2016;66(4):271–289. - PubMed
-
- Sanford SD, Beaumont JL, Butt Z, Sweet JJ, Cella D, Wagner LI. Prospective longitudinal evaluation of a symptom cluster in breast cancer. J Pain Symptom Manage. 2014;47(4):721–730. - PubMed
-
- Abrahams HJ, Gielissen MF, Schmits IC, Verhagen CA, Rovers MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 2016;27(6):965–974. - PubMed
-
- Reinertsen KV, Engebraaten O, Loge JH, et al. Fatigue during and after breast cancer therapy-a prospective study. J Pain Symptom Manage. 2017;53(3):551–560. - PubMed
-
- Bray VJ, Dhillon HM, Vardy JL. Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv. 2018;12(4):537–559. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
